Literature DB >> 18094848

Corpus callosum index: a practical method for long-term follow-up in multiple sclerosis.

Fernando Faria Andrade Figueira1, Valeria Silva dos Santos, Gustavo Medeiros Andrade Figueira, Angela Correa Marques da Silva.   

Abstract

Rather than acute inflammation, long-standing multiple sclerosis (MS) course is hallmarked by relentless axonal loss and brain atrophy, both with subtle clinical expression and scarcely visible on conventional MRI studies. Brain atrophy imaging has sophisticated methodological requirements, not always practical and accessible to most centers. Corpus callosum (CC) is a major inter-hemispheric white matter bundle, grossly affected by long term MS and easily assessed by MRI. To determine whether a practical imaging method can reliably follow presumed axonal loss in patients with progressive MS, we designed a 5-year prospective open label study, enrolling 128 consecutive patients (75 relapsing-remitting (RR) and 53 secondary-progressive (SP)), on regular immunomodulatory therapy compared to control group, formed by 23 patients with MRI considered normal. On a conventional best mid-sagittal T1W, CC index (CCI) was obtained by measuring anterior, medium and posterior segments of CC, normalized to its greatest anteroposterior diameter using an orthogonal semi-automated linear system. CCI was measured at baseline and at least once yearly. Results were plotted intra-individually; baseline values were used as reference. At baseline, CCI was able to distinguish SP patients from RR and controls, and on follow-up, despite some overlap, demonstrated a progressive reduction from baseline on both RR and SP groups compared to controls. From the third year on, difference between SP and RR patients reached statistical significance, which did not correlated with disability measured by EDSS. So, a corpus callosum index proved practical and feasible to longitudinally demonstrate morphometric callosal changes with potential to be used as a tool for long-term follow-up, mostly in SP patients.

Entities:  

Mesh:

Year:  2007        PMID: 18094848     DOI: 10.1590/s0004-282x2007000600001

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  10 in total

1.  Corpus callosum index and long-term disability in multiple sclerosis patients.

Authors:  Ozgür Yaldizli; Ramin Atefy; Achim Gass; Dietrich Sturm; Stephanie Glassl; Barbara Tettenborn; Norman Putzki
Journal:  J Neurol       Date:  2010-03-03       Impact factor: 4.849

2.  Fatigue and progression of corpus callosum atrophy in multiple sclerosis.

Authors:  Özgür Yaldizli; Stephanie Glassl; Dietrich Sturm; Athina Papadopoulou; Achim Gass; Barbara Tettenborn; Norman Putzki
Journal:  J Neurol       Date:  2011-05-19       Impact factor: 4.849

3.  The association between retinal nerve fibre layer thickness and corpus callosum index in different clinical subtypes of multiple sclerosis.

Authors:  Vedat Cilingir; Muhammed Batur; Mehmet Deniz Bulut; Aysel Milanlioglu; Abdullah Yılgor; Abdussamet Batur; Tekin Yasar; Temel Tombul
Journal:  Neurol Sci       Date:  2017-04-10       Impact factor: 3.307

4.  Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis.

Authors:  Eric C Klawiter; Antonia Ceccarelli; Ashish Arora; Jonathan Jackson; Sonya Bakshi; Gloria Kim; Jennifer Miller; Shahamat Tauhid; Christian von Gizycki; Rohit Bakshi; Mohit Neema
Journal:  J Neuroimaging       Date:  2014-05-09       Impact factor: 2.486

5.  Reliability of measuring regional callosal atrophy in neurodegenerative diseases.

Authors:  Jeroen Van Schependom; Saurabh Jain; Melissa Cambron; Anne-Marie Vanbinst; Johan De Mey; Dirk Smeets; Guy Nagels
Journal:  Neuroimage Clin       Date:  2016-10-15       Impact factor: 4.881

Review 6.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

7.  Pathologic basis of the preferential thinning of thecorpus callosum in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Authors:  Michiaki Kinoshita; Kiyomitsu Oyanagi; Yasufumi Kondo; Keisuke Ishizawa; Kenji Ishihara; Mari Yoshida; Teruhiko Inoue; Yoshio Mitsuyama; Kunihiro Yoshida; Mitsunori Yamada; Yoshiki Sekijima; Shu-Ichi Ikeda
Journal:  eNeurologicalSci       Date:  2021-01-22

8.  Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosis.

Authors:  Satori Ajitomi; Juichi Fujimori; Ichiro Nakashima
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-01-05

9.  Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.

Authors:  Arwa Rekik; Mona Aissi; Islem Rekik; Mariem Mhiri; Mahbouba Ayed Frih
Journal:  Brain Behav       Date:  2022-04-10       Impact factor: 3.405

10.  Relationship between Stereoscopic Vision, Visual Perception, and Microstructure Changes of Corpus Callosum and Occipital White Matter in the 4-Year-Old Very Low Birth Weight Children.

Authors:  Przemko Kwinta; Izabela Herman-Sucharska; Anna Leśniak; Małgorzata Klimek; Paulina Karcz; Wojciech Durlak; Magdalena Nitecka; Grażyna Dutkowska; Anna Kubatko-Zielińska; Bożena Romanowska-Dixon; Jacek Józef Pietrzyk
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.